Improved ocular bioavailability of indomethacin by novel ocular drug carriers.
about
Nanomedicine approaches for corneal diseasesBioadhesive hyaluronan-chitosan nanoparticles can transport genes across the ocular mucosa and transfect ocular tissue.Influence of emulsion droplet surface charge on indomethacin ocular tissue distribution.The potential of chitosan in ocular drug delivery.Cationic vectors in ocular drug delivery.Advanced delivery of ciclosporin A: present state and perspective.Ocular drug delivery: nanomedicine applications.Topical ocular delivery of NSAIDs.Chitosan nanoparticles for drug delivery to the eye.Nanocarriers' entry into the cell: relevance to drug delivery.New techniques for drug delivery to the posterior eye segment.Ocular drug delivery - a look towards nanobioadhesives.Polymeric nanoparticles, nanospheres and nanocapsules, for cutaneous applications.In situ gel systems as 'smart' carriers for sustained ocular drug delivery.Ocular drug delivery system: a reference to natural polymers.Impacts of nanomedicines in ocular pharmacotherapyMicroemulsion: new insights into the ocular drug delivery.Topical delivery of ocular therapeutics: carrier systems and physical methods.Colloidal drug delivery system: amplify the ocular delivery.Nanocarriers for ocular delivery for possible benefits in the treatment of anterior uveitis: focus on current paradigms and future directions.Gelatin-based particulate systems in ocular drug delivery.Polymer assisted entrapment of netilmicin in PLGA nanoparticles for sustained antibacterial activity.Formulation, characterization and testing of tetracaine hydrochloride-loaded albumin-chitosan microparticles for ocular drug delivery.Liposomal flucytosine capped with gold nanoparticle formulations for improved ocular delivery.Therapeutic possibilities of ceftazidime nanoparticles in devastating pseudomonas ophthalmic infections; keratitis and endophthalmitis.Development of dorzolamide hydrochloride in situ gel nanoemulsion for ocular delivery.Relevance of Lipid-Based Products in the Management of Dry Eye Disease.Tocopheryl succinate-based lipid nanospheres for paclitaxel delivery: preparation, characters, and in vitro release kinetics.A reverse microemulsion polymerization method for preparation of bioadhesive polyacrylic acid nanoparticles for mucosal drug delivery: loading and release of timolol maleate.Preparation of poly(D,L-lactide) nanoparticles assisted by amphiphilic poly(methyl methacrylate-co-methacrylic acid) copolymers.Design and optimization of surfactant-based nanovesicles for ocular delivery of Clotrimazole.Formulation Development and Evaluation of the Therapeutic Efficacy of Brinzolamide Containing Nanoemulsions.Effect of solid lipid nanoparticles formulation compositions on their size, zeta potential and potential for in vitro pHIS-HIV-hugag transfection.Ocular Drug Delivery.Influence of acetazolamide loading on the (in vitro) performances of non-phospholipid-based cationic nanosized emulsion in comparison with phospholipid-based anionic and neutral-charged nanosized emulsions.Polymeric nanocapsules: a potential new therapy for corneal wound healing.Ocular Drug Delivery Barriers-Role of Nanocarriers in the Treatment of Anterior Segment Ocular Diseases.Advances in the topical ocular drug delivery
P2860
Q27022253-89B540FA-891B-48CF-B4CA-E5C84B8B6395Q33321483-3FA5996E-27EF-4B32-B133-9BD0ADC6C523Q33927480-A07C2927-55C8-4FBF-8FE3-05BFDCC83128Q35624563-507999E6-A6F9-4936-ABAB-6AF0616ECF3AQ35994783-50106E6C-4777-454A-ABB6-E8A7E9E30C07Q36903791-3A40D70D-D72B-42CB-A413-91330A5F5ECDQ36918036-46B02186-7C84-4E85-840B-6CC63D952B19Q37147923-D9AFF908-C33D-4E40-8A4E-527DA22F852AQ37416144-6652D4E1-02E3-460D-A2E3-D530D596CD83Q37508725-75AB5556-8790-47F4-B73A-4770F82451C7Q37692245-86088C24-B309-43C2-9CCA-28516EC57F44Q37822756-7ED8006D-8A6E-4545-BF2A-61CBEA4FDF9DQ37928912-F5E73981-A058-4CB8-855B-45F1220C135AQ37995297-D7282059-EEDA-4D09-A667-B81DC77646DDQ38019052-C311B215-B951-489D-9EB0-A61371255E40Q38107200-106803EC-F491-4F0C-ADD1-BBF38CEAA38FQ38128310-16ECCACC-BC8F-4B39-8452-D20F5CEE0B38Q38196446-8708C21E-EF43-42D7-B7A9-6DB00002B85EQ38217270-D4C86494-5F3E-4D52-9EA3-955F0717ECB2Q38227621-46B38B94-054F-420F-80C5-6EDE1A287AB5Q38310627-08698E73-FF6E-4140-B1F0-F031EA212FEBQ38955018-E5AD4AB2-5DEB-4794-8269-F9671AA1EE20Q39754854-CFB6B4DA-6021-4F22-9CBE-59453D958014Q40809158-F4EC2E8C-3BD6-47C7-9B18-7AE54CF8CF3EQ41990274-3D5474B7-70C8-4B2E-A875-7A6006B07AC8Q43025578-479BA1B3-22FD-4B03-AE88-4A5F2CB07C2EQ43119649-2471DD0E-6070-4C27-B081-1727D222ECD1Q43235073-9B9C0DD2-46E9-4654-8248-A9BD0EEBA553Q43561057-11AE0317-9E5A-4841-AE2A-E80D6DBD9D76Q43661506-4023D58B-BBD2-4B8F-86DF-CC3464871C4DQ45889086-B85B06BE-B132-455F-8F23-2817504C5045Q47143413-41F3B5B7-3663-4E8B-BD15-E6355D92CD96Q47295384-2741E31C-7AA1-408E-A936-C5D41ADB1DFFQ51122641-2E57BBF7-3CC4-47D3-B339-9679777E7068Q51589973-93C5471F-80E1-4C8E-ACA5-251D82E2E0CCQ51654129-EAF112CC-A4A6-4541-AC2F-59F2CC4A6B69Q52679059-820EE037-104A-4230-BA5C-A7672236C091Q57381952-3CBE6F08-1BFB-4627-99F8-DEC005D0D35B
P2860
Improved ocular bioavailability of indomethacin by novel ocular drug carriers.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
1996年论文
@zh
1996年论文
@zh-cn
name
Improved ocular bioavailability of indomethacin by novel ocular drug carriers.
@en
type
label
Improved ocular bioavailability of indomethacin by novel ocular drug carriers.
@en
prefLabel
Improved ocular bioavailability of indomethacin by novel ocular drug carriers.
@en
P2093
P1476
Improved ocular bioavailability of indomethacin by novel ocular drug carriers.
@en
P2093
Robinson JR
Vila-Jato JL
P2860
P304
P356
10.1111/J.2042-7158.1996.TB03911.X
P577
1996-11-01T00:00:00Z